Simplify Logo
Alphatec Spine

Alphatec Spine

Develops and markets spinal surgery solutions

Associate Sales Representative

Full-Time
No salary listed
Mid
Bachelor's
Des Moines, IA, USA
Hybrid

About the job

Requirements
  • Willingness to comply with Commercial policies, including annual training and certification requirements.
  • Strong business and functional acumen.
  • Specific knowledge of orthopedic medical devices and general operating room protocols.
  • Ability to communicate and organize effectively.
  • Ability to independently set and meet aggressive goals and objectives.
  • Ability to work collaboratively to accomplish results.
  • High school education.
  • At least 3 years of experience in spine and/or orthopedics.
  • Eligibility to obtain and maintain credentials at all required hospitals, including compliance with applicable physical and vaccination requirements, including the COVID-19 vaccine where applicable.
Responsibilities
  • Develop and implement sales strategies to achieve quota and increase market share within targeted areas, cities, hospitals, and physician accounts.
  • Grow business within the assigned area of responsibility.
  • Achieve monthly, quarterly, and annual sales goals.
  • Collaborate with sales management to establish territory selling strategies and tactics.
  • Respond to customer needs, requirements, and problems in accordance with company policy.
  • Develop relationships with surgeons and other appropriate contacts within target accounts.
  • Manage and monitor the sales order process to ensure customer satisfaction.
  • Maintain account records and report activities as required by the company.
  • Follow Alphatec training and procedural requirements, including annual certifications.
  • Coordinate product shipping schedules and delivery of merchandise and services.
  • Participate in sales meetings, trade shows, conventions, and other company or industry events as requested.
  • Use analytics and technology to support business decisions.
  • Perform additional duties as assigned.
Desired Qualifications
  • Spine experience.
  • Prior sales experience.
  • A college degree.

About the company

Alphatec Spine develops and sells implants, instruments, and integrated technologies for spine surgery, including devices used in fusion procedures and related navigation or imaging systems gained through acquisitions like SafeOp Surgical. During surgery, surgeons use these implants and instruments, often with imaging or navigation tools to plan and guide the procedure, while the implants support fusion and healing. It differentiates itself with a broad product portfolio and enhanced technology through strategic acquisitions, giving it capabilities in navigation and advanced spine solutions beyond a narrow line of implants. Its goal is to improve spinal surgery outcomes and expand access to effective spine-care solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Carlsbad, California

Founded

1990

Get referred to Alphatec Spine

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $214 million, up 15%, with surgical revenue up 17%.
  • Adjusted EBITDA jumped 53% to $36 million, lifting margin to 17%.
  • The new $300 million credit facility cuts annual interest expense over $6 million.

What critics are saying

  • EOS revenue fell to $14 million in Q1 2026, forcing guidance down to $77 million.
  • Kirby McInerney and Ademi investigated May 2026 disclosures after the 32% stock drop.
  • A prolonged EOS failure plus litigation can choke refinancing and trigger a dilution spiral.

What makes Alphatec Spine unique

  • Alphatec’s EOS imaging and SafeOp bundle intraoperative planning, navigation, and neuro-monitoring.
  • Patrick Miles built a surgeon-adoption playbook, adding 24% net new surgeons in Q2 2026.
  • U.S.-centric direct-sales execution keeps Alphatec close to hospital buying committees.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Sick Leave

Paid Holidays

Disability Insurance

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Sep 14th, 2026
Alphatec surges 19.7% on Q2 results, expects $882M revenue for 2026

Alphatec shares surged 19.7% to $10.58, driven by investor optimism following strong second-quarter 2026 results. The medical equipment company reported earnings per share of 7 cents and revenues of $213.5 million for the quarter. The company maintains its full-year 2026 revenue guidance of approximately $882 million, supported by strong case volume growth, increased surgeon adoption, expanding profitability and positive free cash flow generation. For the upcoming quarter, Alphatec expects earnings of $0.11 per share, representing a 266.7% year-over-year increase. Revenues are projected at $224.28 million, up 14.1% from the prior year. However, the consensus earnings estimate has remained unchanged over the past 30 days. The stock currently carries a Zacks Rank #3 (Hold).

Yahoo Finance
Aug 5th, 2026
Alphatec delivers $214M revenue and 53% adjusted EBITDA growth despite biologics headwinds

Alphatec Holdings reported strong Q2 2026 results with total revenue of $214 million, up 15% year-over-year, and surgical revenue of $196 million, up 17%. The medical device company saw adjusted EBITDA rise 53% to $36 million, with margins expanding 420 basis points to 17%. The company added 24% more net new surgeons and posted 20% case volume growth. Gross margin improved 260 basis points to 72.5%, driven by better inventory efficiency and favourable product mix. Alphatec generated positive free cash flow of approximately $1 million in Q2 and raised full-year adjusted EBITDA guidance to $140 million from $134 million previously. However, revenue per case declined 2.7% due to case mix shifts and international growth. The company now expects full-year revenue per case to decline in the low single digits, citing slower biologics attachment improvement.

Yahoo Finance
Jun 11th, 2026
Alphatec grows revenue 25% to $764M but posts $143M loss with 17.2x debt-to-equity ratio

Alphatec, a spine surgery technology company, reported revenue of $764.2 million in FY 2025, up 25% year-over-year, but posted a net loss of $143.4 million. The company's debt-to-equity ratio stands at approximately 17.2x, whilst its current ratio is 2.1x. Stock-based compensation represented roughly 163% of operating cash flow. Inspire Medical Systems specialises in neurostimulation therapy for obstructive sleep apnea patients who cannot use standard breathing machines. The company targets sleep specialists and ENT surgeons globally. Alphatec differentiates itself through an integrated ecosystem using subsidiaries like EOS imaging and SafeOp Surgical, serving primarily the US hospital market whilst expanding into Europe and Japan. Both companies operate in medical technology but represent different maturity levels and financial profiles for investors seeking healthcare device exposure.

Yahoo Finance
Jun 1st, 2026
Alphatec posts 17% surgical revenue growth, cuts interest expenses by $6M with new bank facility

Alphatec Holdings, a medical technology company specialising in spinal surgery solutions, reported strong first-quarter 2026 results with surgical revenue up 17% and total revenue growing 14% to $192 million. The company achieved non-GAAP adjusted EBITDA of $21 million whilst securing a new bank facility that reduces annual interest expenses by over $6 million. Growth was driven by a 21% increase in surgical case volume and 23% rise in net new surgeon users. The company reported an ending cash balance of $140 million and trailing twelve-month free cash flow of $7 million. For full-year 2026, Alphatec expects total revenue of approximately $882 million, representing 15% growth, with adjusted EBITDA projected at $134 million and at least $20 million in free cash flow generation.

Business Wire
May 19th, 2026
Law firm investigates Alphatec after shares plunge 32% on missed EOS revenue guidance

Kirby McInerney LLP is investigating potential securities law violations by Alphatec Holdings and its senior management following a sharp share price decline. On 5 May 2026, Alphatec reported first quarter revenue of $192 million and disclosed that EOS revenue, from its proprietary imaging platform, was $14 million—below internal expectations. The company reduced its full-year 2026 EOS revenue guidance to approximately $77 million from $85 million, citing execution issues with equipment installations. Management stated that "installation timing was a challenge" and the company failed to fulfill committed units. Following the announcement, Alphatec shares fell 32%, from $10.23 to $6.99 per share. No lawsuit has been filed yet, and the investigation is ongoing to determine whether claims may be brought under federal securities laws.